Susan A. Charman

Susan A. Charman

Auto-generated profile, based on publicly available information

Susan A. Charman

Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Pharmacological Reviews
Verified
Journal Article
Closed access
PDF file
HWHywel D. Williams
Hywel D. Williams
NTNatalie Trevaskis
Natalie Trevaskis
SCSusan A. Charman
Susan A. Charman
RSRavi M. Shanker
Ravi M. Shanker
WCWilliam N. Charman
William N. Charman
CPChristopher J. H. Porter
Christopher J. H. Porter
Drugs with low water solubility are predisposed to low and variable oral bioavailability and, therefore, to variability in clinical response. Despite significant efforts to “design in” acceptable developability properties (including aqueous solubility) during lead optimization, approximately 40% of currently marketed compounds and most current drug development candidates remain poorly water-soluble. The fact that so many drug candidates of this type are advanced into development and clinical assessment is testament to an increasingly sophisticated understanding of the approaches that can be taken to promote apparent solubility in the gastrointestinal tract and to support drug exposure after oral administration. Here we provide a detailed commentary on the major challenges to the progression of a poorly water-soluble lead or development candidate and review the approaches and strategies that can be taken to facilitate compound progression. In particular, we address the fundamental principles that underpin the use of strategies, including pH adjustment and salt-form selection, polymorphs, cocrystals, cosolvents, surfactants, cyclodextrins, particle size reduction, amorphous solid dispersions, and lipid-based formulations. In each case, the theoretical basis for utility is described along with a detailed review of recent advances in the field. The article provides an integrated and contemporary discussion of current approaches to solubility and dissolution enhancement but has been deliberately structured as a series of stand-alone sections to allow also directed access to a specific technology (e.g., solid dispersions, lipid-based formulations, or salt forms) where required.

1 July 2008 in Neuron
Verified
Journal Article
Closed access
PAPaul A. Adlard
Paul A. Adlard
RCRobert A. Cherny
Robert A. Cherny
DFDavid I. Finkelstein
David I. Finkelstein
EGElisabeth Gautier
Elisabeth Gautier
ERElysia Robb
Elysia Robb
Ashley I. BushAshley I. Bush
Ashley I. Bush

1 August 2004 in Nature
Verified
Journal Article
Closed access
PDF file
JVJonathan Vennerstrom
Jonathan Vennerstrom
SASarah Arbe-Barnes
Sarah Arbe-Barnes
RBReto Brun
Reto Brun
SCSusan A. Charman
Susan A. Charman
FCFrancis C. K. Chiu
Francis C. K. Chiu
WCWilliam N. Charman
William N. Charman

17 June 2015 in Nature
Verified
Journal Article
Open access
PDF file
BBBeatriz Baragaña
Beatriz Baragaña
IHIrene Hallyburton
Irene Hallyburton
MLMarcus C. S. Lee
Marcus C. S. Lee
NNNeil R. Norcross
Neil R. Norcross
RGRaffaella Grimaldi
Raffaella Grimaldi
IGIan H. Gilbert
Ian H. Gilbert
There is an urgent need for new drugs to treat malaria, with broad therapeutic potential and novel modes of action, to widen the scope of treatment and to overcome emerging drug resistance. Here we describe the discovery of DDD107498, a compound with a potent and novel spectrum of antimalarial activity against multiple life-cycle stages of the Plasmodium parasite, with good pharmacokinetic properties and an acceptable safety profile. DDD107498 demonstrates potential to address a variety of clinical needs, including single-dose treatment, transmission blocking and chemoprotection. DDD107498 was developed from a screening programme against blood-stage malaria parasites; its molecular target has been identified as translation elongation factor 2 (eEF2), which is responsible for the GTP-dependent translocation of the ribosome along messenger RNA, and is essential for protein synthesis. This discovery of eEF2 as a viable antimalarial drug target opens up new possibilities for drug discovery.

2 January 2020 in Malaria Journal
Verified
Journal Article
Open access
PDF file
SCSusan A. Charman
Susan A. Charman
AAAlice Andreu
Alice Andreu
HBHelena Barker
Helena Barker
SBScott Blundell
Scott Blundell
ACAnna Campbell
Anna Campbell
NANada Abla
Nada Abla
Background: Modelling and simulation are being increasingly utilized to support the discovery and development of new anti-malarial drugs. These approaches require reliable in vitro data for physicochemical properties, permeability, binding, intrinsic clearance and cytochrome P450 inhibition. This work was conducted to generate an in vitro data toolbox using standardized methods for a set of 45 anti-malarial drugs and to assess changes in physicochemical properties in relation to changing target product and candidate profiles.Methods: Ionization constants were determined by potentiometric titration and partition coefficients were measured using a shake-flask method. Solubility was assessed in biorelevant media and permeability coefficients and efflux ratios were determined using Caco-2 cell monolayers. Binding to plasma and media proteins was measured using either ultracentrifugation or rapid equilibrium dialysis. Metabolic stability and cytochrome P450 inhibition were assessed using human liver microsomes. Sample analysis was conducted by LC–MS/MS.Results: Both solubility and fraction unbound decreased, and permeability and unbound intrinsic clearance increased, with increasing Log D7.4. In general, development compounds were somewhat more lipophilic than legacy drugs. For many compounds, permeability and protein binding were challenging to assess and both required the use of experimental conditions that minimized the impact of non-specific binding. Intrinsic clearance in human liver microsomes was varied across the data set and several compounds exhibited no measurable substrate loss under the conditions used. Inhibition of cytochrome P450 enzymes was minimal for most compounds.Conclusions: This is the first data set to describe in vitro properties for 45 legacy and development anti-malarial drugs. The studies identified several practical methodological issues common to many of the more lipophilic compounds and highlighted areas which require more work to customize experimental conditions for compounds being designed to meet the new target product profiles. The dataset will be a valuable tool for malaria researchers aiming to develop PBPK models for the prediction of human PK properties and/or drug–drug interactions. Furthermore, generation of this comprehensive data set within a single laboratory allows direct comparison of properties across a large dataset and evaluation of changing property trends that have occurred over time with changing target product and candidate profiles.

15 July 2015 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
MPMargaret A. Phillips
Margaret A. Phillips
JLJulie Lotharius
Julie Lotharius
KMKennan Marsh
Kennan Marsh
JWJohn White
John White
ADAnthony Dayan
Anthony Dayan
SCSusan A. Charman
Susan A. Charman
The antimalarial drug DSM265 displays activity against blood and liver stages of Plasmodium falciparum and has a long predicted half-life in humans.